Treatment of pituitary gland hyperfunction: From acromegaly to prolactinoma;Therapie der hypophysenüberfunktion: Von der akromegalie zum prolaktinom

Internist

Volumn 47, Issue 12, 2006, Pages 1215-1222

  Schaffler A ^a,b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Acromegaly; Dopamine agonist; Pituitary gland; Prolactinoma; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; QUINAGOLIDE;

ACROMEGALY; EVIDENCE BASED PRACTICE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE SECRETING CELL; HUMAN; PATIENT ASSESSMENT; PREGNANCY; PROLACTINOMA; REVIEW; TRANSSPHENOIDAL SURGERY;

ACROMEGALY; ADENOMA; COMBINED MODALITY THERAPY; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; HYPERPITUITARISM; HYPOPHYSECTOMY; PITUITARY NEOPLASMS; PREGNANCY; PROLACTINOMA; RECEPTORS, SOMATOTROPIN; SOMATOSTATIN;

EID: 33845878786     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-006-1727-3     Document Type: Review

References (42)

1. Abs R, Verhelst J, Maiter D et al. (1998) Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83: 374-378
2. Bevan JS (2005) Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90: 1856-1863
3. Biller BM, Molitch ME, Vance ML et al. (1996) Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81: 2338-2343
4. Bronstein M, Musolino N, Jallad R et al. (2005) Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90, or 120 mg every 28 days. Clin Endocrinol 63: 514-519
5. Caron P, Bex M, Cullen DR et al. (2004) One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol 60: 734-740
6. Clemmons DR, Chihara K, Freda PU et al. (2003) Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 88: 4759-4767
7. Colao A, Di Sarno A, Landi ML et al. (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82: 3574-3579
8. Colao A, Di Sarno A, Cappabianca P et al. (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349: 2023-2033
9. Colao A, Vitale G, Cappabianca P et al. (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89: 1704-1711
10. Cook DM (2005) Long-term management of prolactinomas - use of long-acting dopamine agonists. Rev Endocr Metab Disord 6: 15-21
11. Corenblum B, Donovan L (1993) The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 59: 671-673
12. Cozzi R, Attanasio R, Montini M et al. (2003) Four-year treatment with octreotide long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88: 3090-3098
13. Feenstra J, de Herder WW, ten Have SM et al. (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365: 1644-1646
14. Freda PU (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87: 3013-3018
15. Gemzell C, Wang CF (1979) Outcome of pregnancy in women with pituitary adenoma. Fertil Steril 31: 363-372
16. Giusti M, Ciccarelli E, Dallabonzana D et al. (1997) Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest 27: 277-284
17. Giustina A, Barkan A, Casanueva FF et al. (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85: 526-529
18. Gutt B, Bidlingmaier M, Kretschmar K et al. (2005) Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes 113: 139-144
19. Gutt B, Steffin B, Schopohl J (2005) Medikamentöse Therapie von Hypophysenerkrankungen. Internist 10: 1158-1165
20. van der Hoek J, van der Lelij AJ, Feelders RA et al. (2005) The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin Endocrinol 63: 176-184
21. Katznelson L (2005) Diagnosis and treatment of acromegaly. Growth Horm IGF Res 15: S31-35
22. Kohler B PK, Reichardt B, Schopohl J et al. (1996) Long-term treatment of macroprolactinoma patients: a retrospective analysis of patients treated from 1971-1994. In: von Werder K, Fahlbusch R (Eds) Pituitary adenomas: from basic research to diagnosis and therapy. Elsevier, Amsterdam, pp 325-329
23. Krupp P, Monka C (1987) Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65: 823-827
24. Kupersmith MJ, Rosenberg C, Kleinberg D (1994) Visual loss in pregnant women with pituitary adenomas. Ann Intern Med 121: 473-477
25. van der Lely AJ, Hutson RK Trainer PJ et al. (2001) Long-term treatment of acromegaly treated with pegvisomant, a growth hormone receptor antagonist. Lancet 358: 1754-1759
26. van der Lely AJ, Muller A, Janssen JA et al. (2001) Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 86: 478-481
27. Lloyd RJ, Kovacs K, Young WF Jr (2004) Tumours of the pituitary. In: DeLellis RA, Lloyd RV, Heitz PU (Eds) Pathology and genetics: tumours of endocrine tumours. International Agency for Research on Cancer (IARC), Lyon, pp 9-48
28. March CM, Kletzky OA, Davajan V et al. (1981) Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 139: 835-844
29. Melmed S, Sternberg R, Cook D et al. (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90: 4405-4410
30. Molitch ME (1985) Pregnancy and the hyperprolactinemic woman. N Engl J Med 312: 1364-1370
31. Molitch ME (1995) Prolactinomas. In: Melmed S (Ed) The pituitary. Blackwell Science, Cambridge, pp 443-477
32. Molitch ME (1999) Diagnosis and treatment of prolactinomas. Adv Intern Med 44: 117-153
33. Molitch ME (2002) Medical management of prolactin-secreting pituitary adenomas. Pituitary 5: 55-65
34. Newman CB, Melmed S, Snyder PJ et al. (1995) Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. J Clin Endocrinol Metab 80: 2768-2775
35. Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 152: 379-387
36. Petersenn S, Lüdecke DK, Fahlbusch R et al. (2006) Therapie von Hypophysentumoren. Dtsch Ärzteblatt 8: 407-413
37. Schlechte J, Dolan K, Sherman B et al. (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68: 412-418
38. Stefaneanu L, Kovacs K, Horvath E et al. (2001) Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 14: 329-336
39. Trainer PJ, Drake WM, Katznelson L et al. (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342: 1171-1177
40. Verhelst J, Abs R, Maiter D et al. (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84: 2518-2522
41. Wass J (2006) When to discontinue treatment of prolactinoma? Nat Clin Pract Endocrinol Metab 2: 298-299
42. Wingrave SJ, Kay CR, Vessey MP (1980) Oral contraceptives and pituitary adenomas. Br Med J 280: 685-686